News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aerocrine: First Primary Care Trial Supports FeNO-Guided Asthma Treatment



10/11/2013 10:02:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Aerocrine AB (STO:AERO-B) – A new randomised clinical trial shows lower incidence of asthma exacerbations and increased asthma control with Fractional exhaled Nitric Oxide (FeNO)-guided anti-inflammatory treatment. The study has been published on the website of Journal of Allergy and Clinical Immunology: In Practice (http://www.jaci-inpractice.org/article/S2213-2198(13)00352-8/abstract). A total of 187 non-smoking asthma patients (18-64 years) with perennial allergy and on regular inhaled corticosteroid (ICS) treatment were recruited at 17 primary health care centres in Sweden, randomly assigned to two groups and followed for one year. One group was treated with standard of care whereas treatment of the patients in the other group were guided by FeNO. Aerocrine’s patented FeNO test, with the NIOX® MINO® device was used in the study. In the standard of care group FeNO was blinded for both patient and physician.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Aerocrine
 
 
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES